LinkedIn
WebsiteIntroduction
SCISPARC LTD (NASDAQ: SPRC; name in Korean: 사이스파크) is a clinical-stage pharmaceutical company specializing in cannabinoid-based therapies. The company is advancing four drug candidates in clinical trials and two in pre-clinical studies. Indications under investigation include Tourette syndrome, obstructive sleep apnea, Alzheimer’s disease, agitation, autism spectrum disorder, status epilepticus, and chronic pain.
| Ticker | Exchange | Price (USD) | Change (%) | Volume |
|---|---|---|---|---|
| SPRC | NAS | 3.9592 | +115.17 | 5,597,585 |
Corporate Structure
SCISPARC employs between 11 and 50 staff, reflecting a focused, project-driven operation. The executive team combines expertise in biochemistry, pharmacology, manufacturing, and regulatory affairs. Oz Adler, CPA, serves as both CEO and CFO, overseeing financial strategy and capital management. The scientific advisory board includes individuals with experience in drug development and international distribution.
Cannabinoid therapy by Buzzed Buds
Recent Developments and News
On August 29, 2025, SCISPARC reported the sale of $4.2 million in convertible debentures, convertible into ordinary shares at 95 percent of the subscription price. By August 28, 2025, investors had converted a portion of these instruments into 999,528 ordinary shares, leaving $175,000 in debentures outstanding and bringing total shares issued and outstanding to 1,622,273.
A Form 6-K filing dated September 8, 2025, disclosed that the Israeli Securities Authority and law enforcement conducted searches related to an investigation involving AutoMax Motors Ltd., resulting in the detention of senior officers. This investigation poses legal and reputational risks amid SCISPARC’s pending merger with AutoMax.
A subsequent filing on September 16, 2025, revealed that the merger proceedings are stayed until September 30, 2025, at the request of AutoMax. This stay introduces uncertainty regarding the fulfillment of closing conditions.
Financial and Strategic Analysis
SCISPARC’s issuance of convertible debentures in February 2025 provided $4.2 million in capital, delaying equity dilution. The August conversions indicate investor interest; however, the remaining $175,000 in debt continues to be a factor in the capital structure. Management’s dual roles in finance and operations reflect a coordinated approach to funding research and development.
The merger with AutoMax Motors represents a strategic initiative, though the ongoing legal investigation and court-ordered stay introduce execution risk. Investors should consider the potential for operational expansion alongside the implications of the unresolved legal matters and the feasibility of completing the merger by the set date.
Market Position and Industry Context
SCISPARC operates in the emerging landscape of cannabinoid therapeutics, competing with both established pharmaceutical companies and smaller biotech firms. The company’s drug pipeline targets areas with significant unmet medical needs—such as Tourette syndrome and autism spectrum disorder—where few approved treatments exist. Regulatory scrutiny of cannabinoid products remains strict, but successful clinical trial outcomes and regulatory approvals could enhance SCISPARC's position within this sector.
tl;dr
As of September 17, 2025, SCISPARC’s share price increased by 115.17 percent to $3.96 amid heightened trading volume. The company has converted a majority of its February convertible debentures into equity, thereby reducing debt exposure. However, a pending merger with AutoMax Motors is paused by a court stay until September 30, and ongoing investigations into AutoMax may affect the execution of the merger. Stakeholders will continue to monitor the merger progress and developments in clinical trials for insights regarding SCISPARC’s future direction.
